A novel hypoglycemic agent: polysaccharides from laver (Porphyra spp.)
Aoqiong Zeng1, Ruijin Yang1, Shuhuai Yu1
1State Key Laboratory of Food Science and Technology, School of Food Science and Technology, Jiangnan University, 1800 Lihu Avenue, Wuxi, Jiangsu 214122, P.R. China and National Engineering Research Center for Functional Food, Jiangnan University, 1800 Lihu Avenue, Wuxi, Jiangsu 214122, P.R. China and Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Jiangnan University, 1800 Lihu Avenue, Wuxi, Jiangsu 214122, P.R. China. shuhuai@jiangnan.edu.cn zhaow@jiangnan.edu.cn.
Abstract:
Type-II diabetes mellitus (T2DM) has become one of the most prevalent diseases on Earth and some treatments have been developed to manage it. One intestinal enzyme α-amylase can break down starch to glucose. Inhibiting its activity will control blood glucose and provide an essential approach for the management of T2DM. Alpha-amylase inhibitor (α-AI) specifically inhibits the activity of α-amylase, and reduces the blood glucose level efficiently. To develop a novel α-AI, the red seaweed laver (Porphyra spp.) was exploited in this work, whose extracts contain polysaccharides showing an inhibitory effect against α-amylase. The crude polysaccharides were extracted using hot water (85 °C) and degraded to low-molecular-weight polysaccharides with 7% of H2O2. One polysaccharide PD-1 exhibiting a competitive binding mode with an IC50 of 12.72 mg mL-1 was separated from these degraded polysaccharides, showing approximately 98.78% of α-amylase inhibition activity. In vivo, PD-1 could efficiently suppress postprandial blood glucose levels in normal and diabetic rats. The polysaccharide inhibitor from red seaweed laver could be regarded as a novel functional food ingredient in T2DM management.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Sulfonylureas
Biosynthesis of Polysaccharides
Oral Hypoglycemic Agents: Biguanides and Glitazones


